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OBJECTIVE—We prospectively examined plasma levels of lep-
tin and soluble leptin receptor (sOB-R), as well as their interac-
tions with other diabetes risk factors, in relation to type 2
diabetes to elucidate the complex relation between these two
biomarkers and diabetes risk.
RESEARCH DESIGN AND METHODS—Of 32,826 Nurses’
Health Study participants who provided blood samples during
1989–1990, 1,054 incident case subjects of type 2 diabetes were
identiﬁed and conﬁrmed during 1990–2004 and 1,254 matched
control subjects were selected. Plasma leptin and sOB-R levels
were measured among these participants.
RESULTS—After multivariate adjustment for BMI, lifestyle
practices, and dietary factors, sOB-R levels were signiﬁcantly
associated with a lower risk of type 2 diabetes. In comparison
with women in the lowest quintile, the ORs (95% CI) of develop-
ing type 2 diabetes were 0.73 (0.55–0.96), 0.51 (0.38–0.68), 0.42
(0.31–0.57), and 0.39 (0.28–0.54; P for trend  0.0001) for women
in the second to ﬁfth quintiles of sOB-R levels, respectively. In
contrast, plasma leptin levels were not signiﬁcantly associated
with the risk of type 2 diabetes: The OR (95% CI) was 0.82
(0.62–1.10; P for trend  0.46) comparing the highest with the
lowest quintile of leptin levels. sOB-R levels were consistently
associated with a decreased risk of type 2 diabetes at various
levels of leptin or high-molecular-weight adiponectin.
CONCLUSIONS—These data suggest a strong inverse associa-
tion between plasma sOB-R levels and risk of type 2 diabetes,
independent of BMI, leptin, and adiponectin levels. Diabetes 59:
611–618, 2010
L
eptin, a 16-kDa protein produced primarily in
adipose tissue (1), is a pleiotropic hormone that
is involved in body weight regulation, puberty,
reproduction, and immune function (2–4). Al-
though accumulating evidence suggests that leptin may
also directly interact with insulin on glucose metabolism
(3), conﬂicting results have been generated for the effects
of leptin on insulin sensitivity in animal models and
humans (5) and for circulating leptin levels in relation to
type 2 diabetes in humans (6–14). These mixed results
indicate that other regulatory factors may modulate the
effects of leptin on insulin sensitivity or diabetes. Soluble
leptin receptors (sOB-Rs) that provide the primary leptin-
binding capacity in human circulation (15) have been
suggested to be such a modulating factor because sOB-R
acts as a buffer to maintain the bioavailability of free lep-
tin in the circulation (16). Interestingly, several cross-
sectional studies consistently showed that sOB-R was
inversely correlated with adiposity and insulin resistance
indexes in humans (17–20). However, no prospective data
exist regarding the association between sOB-R and type 2
diabetes risk or the joint effects with leptin on diabetes
risk. Therefore, we performed a prospective case-control
study in the Nurses’ Health Study (NHS) cohort to exam-
ine the associations among leptin, sOB-R, and risk of type
2 diabetes in U.S. women.
RESEARCH DESIGN AND METHODS
The NHS cohort was established in 1976 with 121,700 female registered nurses
aged 30–55 years who were residing in 11 U.S. states and had completed a
mailed questionnaire on their medical history and lifestyle characteristics.
During 1989–1990, upon request, 32,826 women provided blood samples, the
majority (97%) of which were received within 26 h of blood draw. Immediately
upon arrival, whole blood samples were centrifuged and aliquoted into
cryotubes as plasma, buffy coat, and erythrocytes, which were then stored in
the vapor phase of liquid nitrogen freezers at a temperature  130°C.
Among the participants who provided blood samples and were free of
diabetes, cardiovascular disease, and cancer at blood draw, we prospectively
identiﬁed and conﬁrmed 1,054 type 2 diabetes case subjects from the date of
blood draw through June 2004. Using risk-set sampling, one or two control
subjects were randomly selected for each case subject from the rest of the
population who remained free of diabetes and matched to case subjects by
age at blood draw (1 year), date of blood draw (3 months), fasting status
(fasting for 8 h or not fasting), and race. After excluding eight control
subjects with missing leptin or sOB-R data, 1,054 incident type 2 diabetes case
subjects and 1,254 control subjects were available for the current analysis.
The study protocol was approved by the institutional review board of the
Brigham and Women’s Hospital and the Human Subjects Committee Review
Board of Harvard School of Public Health.
Ascertainment of type 2 diabetes. In the NHS, women who reported a
diagnosis of type 2 diabetes in the biennial follow-up questionnaires were sent
supplementary questionnaires inquiring about symptoms, diagnostic tests, and
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2 diabetes has been proven to be accurate in a validation study (21). Of a
random sample of 62 diabetic nurses initially conﬁrmed by the supplementary
questionnaire, 61 (98%) were conﬁrmed by medical records reviewed by an
endocrinologist blinded to the supplementary questionnaire information (21).
In the current study, all case subjects were conﬁrmed using the supplementary
questionnaire. For case subjects diagnosed before 1998, we used the following
criteria from the National Diabetes Data Group for the conﬁrmation of type 2
diabetes diagnosis: 1) an elevated glucose concentration (fasting plasma
glucose 7.8 mmol/l, random plasma glucose 11.1 mmol/l, or plasma
glucose 11.1 mmol/l after an oral glucose load) and at least one symptom
(excessive thirst, polyuria, weight loss, or hunger) related to diabetes; 2)n o
symptoms but elevated glucose concentrations on two occasions; and 3)
treatment with insulin or oral hypoglycemic medication. For case subjects of
type 2 diabetes identiﬁed after 1998, the cutoff point used for fasting plasma
glucose concentrations was lowered to 7.0 mmol/l according to the American
Diabetes Association criteria.
Laboratory procedures. Each case-control pair or triplet was shipped in the
same batch and analyzed in the same run. Within each batch, samples were
assayed by the same technicians in a random sequence under identical
conditions.
Total leptin was measured by a radioimmunoassay (Millipore, Billerica,
MA), the sensitivity of which is 0.5 ng/ml. sOB-R was measured by ELISA
technique (R&D Systems, Minneapolis, MN) with a sensitivity of 0.06 ng/ml.
Laboratory control samples (n  20) were run along with the case-control
samples. Based on the measurements of these control samples, the average
intra-assay coefﬁcient of variation was 7.7% for the leptin assay and 7.3% for
the sOB-R assay. In addition to leptin and sOB-R, total and high-molecular-
weight (HMW) adiponectin, resistin, C-reactive protein, tumor necrosis fac-
tor- receptor 2, interleukin-6 (IL-6), interleukin-18 (IL-18), fasting insulin, and
C-peptide were also measured for all or some of the case and control subjects.
The assays for these biomarkers have been described elsewhere (22–24).
Assessment of lifestyle and dietary covariates. In baseline and/or subse-
quent biennial follow-up questionnaires, information on major lifestyle risk
factors for chronic diseases, such as body weight, cigarette smoking, physical
activity, family history of diabetes, menopausal status, and postmenopausal
hormone use, was collected and updated in the NHS cohort. BMI as weight in
kilograms divided by the square of height in meters (kg/m
2) was calculated to
assess overall adiposity. We asked the participants to measure their waist
circumference (at umbilicus) and hip circumference (the largest circumfer-
ence) in 1986. From 1980, diet was assessed using a validated semiquantitative
food frequency questionnaire every 2–4 years. Nutrient intake was calculated
based on responses to the food frequency questionnaire and the nutrient
content of foods was derived from the Harvard Food Composition Database.
Statistical methods. We evaluated the correlation of leptin and sOB-R with
anthropometric measurements and plasma concentrations of inﬂammatory
markers and adipokines among control subjects. Spearman partial correlation
coefﬁcients were calculated, adjusted for age at blood draw (years), date of
blood draw, fasting status (8 h versus 8 h since last meal), race, BMI (kg/m
2),
smoking status (never smoked, former smoker, or current smoker), post-
menopausal status (yes/no), hormone use (never used, former user, current
user), family history of diabetes (yes/no), and physical activity and alcohol
intake (both in quintiles). Because we observed a strong correlation between
leptin biomarkers and BMI (Table 2), we calculated the BMI-adjusted residu-
als of the biomarkers by regressing each biomarker on BMI at blood draw
using linear regressions and used these residuals in the subsequent analysis.
These residuals are statistically independent of BMI and, therefore, are
subject to minimal residual confounding by BMI. This approach has been
described in detail elsewhere (25).
We categorized the study population into quintiles according to the
distribution of the BMI-adjusted levels of biomarkers among control subjects.
We used both conditional and unconditional logistic regressions to examine
the associations of interest, and because the ﬁndings were similar, we
presented the results only from unconditional logistic regressions. In the
multivariate analysis, we controlled for the aforementioned lifestyle covari-
ates, as well as intake of alcohol, cereal ﬁber, heme iron, trans fat, magne-
sium, coffee, and red meat (all in quintiles). All lifestyle covariates were
derived from the questionnaire administered in 1990 or the nearest year prior
to 1990. Because we have multiple assessments of dietary factors, we
calculated the average of nutrient intake in 1980, 1984, 1986, and 1990 to
minimize measurement errors and better represent long-term diet (26). The
chosen lifestyle and dietary covariates were either matching factors that
should be adjusted when using unconditional regression to derive ORs in a
nested case-control study (27) or established diabetes risk factors that were
also correlated with leptin or sOB-R levels. P values for linear trend were
calculated by entering an ordinal score based on the median value in each
quintile of leptin biomarkers into the multivariate models. When we examined
potential interactions between leptin biomarkers and lifestyle/dietary risk
factors, we used tertiles of the biomarkers to preserve statistical power and to
gain more stable estimates of the OR. We constructed interaction terms
between biomarker tertiles and the interacting factors of interest and used
likelihood ratio tests to assess the signiﬁcance of these interaction terms.
Likelihood ratio tests are calculated as the difference of 2 log likelihood in
models with and without interaction terms and follow the 
2 distribution with
the degree of freedom equal to the number of parameters for the interaction
terms. In addition, we used restricted cubic spline regressions with three
knots (28) to examine possible nonlinear relationships between leptin biomar-
kers and risk of type 2 diabetes. Tests for nonlinearity used the likelihood ratio
test, comparing the model with only the linear term to the model with the
linear and the cubic spline terms.
All P values were two-sided, and 95% CIs were calculated for ORs. Data
were analyzed with the Statistical Analysis Systems software package, version
9.1 (SAS Institute, Cary, NC).
RESULTS
Table 1 shows the baseline characteristics of study popu-
lation. As expected, type 2 diabetes case subjects had a
higher BMI, lower physical activity levels, higher probabil-
ity of having family history of diabetes, and less healthy
dietary intake at baseline than control subjects. Case
subjects also had signiﬁcantly higher leptin levels but
lower sOB-R levels than control subjects. The distribution
of other inﬂammatory biomarkers and adipokines in case
and control subjects was consistent with our previous
ﬁndings (22–24).
In control subjects, after adjustment for multiple covari-
ates, plasma leptin levels were strongly correlated with
BMI; the partial Spearman correlation coefﬁcient (r) was
0.72 (Table 2). In contrast, sOB-R was signiﬁcantly in-
versely correlated with BMI (r  0.43). To better control
for confounding by BMI, we used BMI-adjusted residuals
of these biomarkers in the subsequent analyses. BMI-
adjusted leptin and sOB-R were not correlated with waist
circumference or waist-to-hip ratio. Signiﬁcantly positive
correlations were found between leptin and C-reactive
protein (r  0.25) and between sOB-R and HMW adiponec-
tin (r  0.26). In a subset of the control subjects with
insulin and C-peptide data, we found no signiﬁcant corre-
lations with insulin but signiﬁcant correlations for leptin
(r  0.18) and sOB-R (r  0.18) with C-peptide.
After multivariate adjustment for established and poten-
tial lifestyle and dietary risk factors for type 2 diabetes,
BMI-adjusted leptin levels were not signiﬁcantly associ-
ated with diabetes risk (Table 3). In contrast, BMI-adjusted
sOB-R levels were signiﬁcantly associated with a lower
risk of type 2 diabetes. Compared with women in the
lowest quintile of sOB-R, women in the highest quintile
had an OR of 0.39 (95% CI: 0.28–0.54; P for trend 
0.0001). This association was attenuated but remained
statistically signiﬁcant after further adjustment for HMW
adiponectin; the OR (95% CI) was 0.67 (0.47–0.95; P for
trend  0.005). Further adjustment for other biomarkers,
including inﬂammatory markers and other adipokines, did
not change the point estimates of these associations
materially, although the 95% CIs were much wider and P
values less signiﬁcant because only half of the study
population had all of these biomarkers available (data not
shown). Lastly, when we further adjusted for fasting
insulin in a subset of the study participants (39% of total
participants) with fasting insulin data, the associations for
sOB-R levels were slightly attenuated, but a statistically
signiﬁcant trend persisted (data not shown).
We found no signiﬁcant deviation from a linear rela-
tionship between sOB-R and risk of type 2 diabetes in
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0.35 (Fig. 1).
Joint associations for sOB-R and leptin, as well as HMW
adiponectin, are shown in Fig. 2. We did not ﬁnd a
signiﬁcant interaction between sOB-R and leptin (P for
interaction  0.09) or HMW adiponectin (P for interac-
tion  0.30). Within each tertile of leptin levels, sOB-R
levels were consistently associated with a lower risk of
type 2 diabetes. In our previous study, HMW adiponectin
was signiﬁcantly associated with a lower risk of type 2
diabetes (24). In the current analysis, sOB-R was associ-
ated with a lower risk within each HMW adiponectin level
and vice versa. Women who were in the highest tertiles of
both sOB-R and HMW adiponectin had the lowest odds of
developing type 2 diabetes; the OR (95% CI) was 0.13
(0.09–0.20) in comparison with women in the lowest
tertiles of these two markers.
We subsequently examined potential interactions of
leptin biomarkers with other risk factors in relation to type
2 diabetes risk (Table 4). Although we did not ﬁnd
signiﬁcant interactions between leptin biomarkers and
risk factors such as age, fasting status, and physical
activity, the association for leptin with diabetes risk was
signiﬁcantly modiﬁed by BMI (P for interaction  0.001).
Leptin was signiﬁcantly associated with a lower risk of
type 2 diabetes in participants with a BMI 30 kg/m
2.I n
contrast, in lean participants (BMI 25 kg/m
2), leptin
levels were associated with a signiﬁcantly increased risk
of type 2 diabetes. Additional adjustment for waist circum-
ference or waist-to-hip ratio did not change these associ-
ations (data not shown).
DISCUSSION
In this nested case-control study conducted in middle-
aged U.S. women, we found that high sOB-R levels were
TABLE 1
Baseline characteristics of type 2 diabetic case and control subjects, the Nurses’ Health Study, 1990
Characteristics* Case subjects Control subjects P†
n 1,054 1,254
Demography and lifestyle
Age (years)‡ 56.0  6.9 56.1  7.0 0.72
BMI (kg/m
2) 30.3  5.5 25.9  4.8 0.0001
Physical activity (MET-h/week) 8.9 (3.8–19.0) 12.8 (5.9–22.8) 0.0001
Alcohol (g/day) 1.1 (0.0–4.0) 2.3 (0.3–8.1) 0.0001
Smoking status (%) 0.21
Never smoked 46.7 47.9
Former smoker 40.1 40.8
Current smoker 13.2 11.3
Menopausal status (%) 0.0001
Premenopausal 22.4 22.3
Postmenopausal, never used hormone 14.2 12.3
Postmenopausal, hormone past user 28.7 37.9
Postmenopausal, hormone current user 34.7 27.5
Family history of diabetes (%) 44.7 22.5 0.0001
Fasting status (%)‡ 64.3 64.1 0.92
Diet
Total energy (kcal/day) 1,822.5  558.5 1,765.9  496.9 0.01
Coffee (cups/day) 2.1  1.6 2.2  1.6 0.02
Fruits and vegetables (servings/day) 5.2  1.9 5.2  1.9 0.99
Red meat (servings/day) 1.2  0.5 1.1  0.5 0.0001
Fish (servings/week) 2.0  1.2 1.8  1.2 0.002
Glycemic load 96.9  15.2 96.6  16.4 0.66
Cereal ﬁber (g/day) 3.8  1.6 4.2  1.8 0.0001
Whole grain (g/day) 14.7  10.1 17.1  11.8 0.0001
Heme iron (mg/day) 1.3  0.3 1.2  0.3 0.0001
Polyunsaturated-to-saturated fat ratio 0.50  0.12 0.51  0.14 0.004
Trans fat (g/day) 1.9  0.5 1.8  0.5 0.003
Magnesium (mg/day) 290.9  55.6 299.2  60.4 0.0006
Biomarker§
Leptin (ng/ml) 29.2  13.8 21.0  13.3 0.0001
sOB-R (ng/ml) 28.0  8.2 34.1  11.0 0.0001
HMW adiponectin (g/ml) 4.4  3.0 8.0  5.4 0.0001
Resistin (ng/ml) 21.0  16.9 17.9  12.4 0.0001
IL-18 (pg/ml) 349.1  186.7 294.5  161.5 0.0001
TNF-R2 (pg/ml) 2,762.7  864.1 2,453.0  792.7 0.0001
IL-6 (ng/ml) 3.1  2.7 2.4  2.4 0.0001
CRP (mg/l) 5.1  5.3 2.4  2.9 0.0001
*For continuous variables, values were expressed as mean  SD or median (interquartile range IQR	); for categoric variables, % was used.
†P values were based on Student t test for continuous variables expressed as mean  SD, Wilcoxon rank-sum test for continuous variables
expressed as median (IQR), or Pearson 
2 test for categoric variables. ‡Matching factor. §For case subjects, tumor necrosis factor- receptor
2 (TNF-R2) was missing for 335, IL-6 was missing for 357, and C-reactive protein (CRP) was missing for 345; for control subjects, TNF-R2
was missing for 730, IL-6 was missing for 749, and CRP was missing for 740. HMW adiponectin, resistin, and IL-18 were missing for 2 control
subjects. MET-h, metabolic equivalent task-h.
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independent of baseline leptin or adiposity levels. On
the other hand, BMI-adjusted leptin levels were not
signiﬁcantly associated with risk of type 2 diabetes.
Our study provided the ﬁrst piece of evidence for an
inverse association between sOB-R levels and risk of
developing type 2 diabetes independent of plasma leptin
levels. Leptin generates its central and peripheral effects
by binding to its receptors on the cell surface and subse-
quently activating downstream signaling pathways (29).
Through posttranscriptional alternative RNA splicing, sev-
eral isoforms of leptin receptors with identical extracellu-
lar and transmembrane domains but variable intracellular
domains are expressed in humans (30). The long form of
leptin receptor with the full length of intracellular domain
is expressed primarily in the hypothalamus, whereas the
short forms of leptin receptor (OB-RS) are expressed
primarily in peripheral tissues (30). sOB-R, a special leptin
receptor with the extracellular domain only, is formed by
ectodomain shedding of leptin receptors on the cell sur-
face (31), and provides the primary binding capacity in
human circulation (15). The function of sOB-R is not
entirely clear but believed to delay the clearance of leptin
from the circulation and, thus, increase leptin’s availability
(16). In addition, there is evidence suggesting that sOB-R
not only alters the clearance of leptin but also potenti-
ates leptin action (32). This is an analogy to the obser-
vation that the action of IL-6 can be boosted by binding
to its soluble receptor (33), which shares a homologous
structure with leptin receptor (34). Furthermore, be-
cause sOB-R levels are highly correlated with the cell
surface expression of leptin receptors (r  0.80) (35),
especially OB-RS, sOB-R may represent the total amount
or biological activity of OB-RS expressed in peripheral
tissues. Unlike long form of leptin receptor, OB-RS does
not contain the intracellular motifs required to activate
the Janus kinase/signal transducers and activators of
transcription signaling pathway that mediates the en-
ergy homeostasis effects of leptin (36). However, accu-
mulating evidence suggests that OB-RS may mediate the
effects of leptin on insulin sensitivity and other periph-
eral effects through a distinct pathway involving insulin
receptor substrate/phosphatidylinositol-3-OH kinase
pathway (37–41). Although more data are needed to
further elucidate sOB-R’s functions, these mechanisms
may underlie the inverse association with diabetes risk
for sOB-R observed in the current study.
Consistent with a previous study (20), we found a
signiﬁcant, positive correlation between sOB-R and HMW
adiponectin in the current study. Both biomarkers are
correlated with lower levels of adiposity and decrease
after weight loss (17,19), and their short-term variations
are nearly identical (42), suggesting these two biomarkers
may share some common regulatory factors. However, the
inverse associations of these two biomarkers were inde-
pendent of each other, and women with high levels of both
biomarkers had dramatically lower risk of developing
diabetes. Whether these two molecules share the same
pathway or affect diabetes risk through distinct pathways
warrants further investigation.
TABLE 2
Partial Spearman correlation coefﬁcients for anthropometric
measurements, adipokines, and inﬂammatory markers among
control subjects
Leptin (ng/ml) sOB-R (ng/ml)
Age (years) 0.07* 0.11*
BMI (kg/m
2) 0.72* 0.43*
Waist circumference (cm) 0.07 0.08†
Waist-to-hip ratio 0.03 0.09*
HMW adiponectin (g/ml) 0.07† 0.26*
Resistin (ng/ml) 0.06† 0.07†
CRP (mg/dl) 0.25* 0.02
TNF-R2 (pg/ml) 0.06 0.01
IL-6 (ng/ml) 0.08 0.07
IL-18 (pg/ml) 0.04 0.01
Insulin (U/ml)‡ 0.06 0.08
C-peptide (pm/ml)‡ 0.18* 0.18*
Leptin (ng/ml) — 0.14*
sOB-R (ng/ml) 0.14* —
Spearman correlation coefﬁcients between biomarkers were ad-
justed for age at blood draw, date of blood draw, fasting status (8
h vs. 8 h since last meal), race, BMI (kg/m
2), smoking status
(never smoked, former smoker, or current smoker), postmeno-
pausal status (yes, no), hormone use (never used, former user,
current user), family history of diabetes (yes, no), and physical
activity and alcohol intake (both in quintiles). BMI-adjusted
residuals of leptin and sOB-R were used except for the correla-
tions with BMI. n  1,254 for leptin, sOB-R, age, and BMI; n  892
for waist circumference and waist-to-hip ratio; n  1,252 for
HMW, resistin, and IL-18; n  492 for C-reactive protein (CRP),
tumor necrosis factor- receptor 2 (TNF-R2), and IL-6. *P  0.01.
†P  0.05. ‡Fasting samples only, n  344.
TABLE 3
ORs (95% CI) of type 2 diabetes for quintiles of plasma leptin and sOB-R levels
Baseline plasma levels P for
trend Q1 (lowest) Q2 Q3 Q4 Q5 (highest)
Leptin (ng/ml), median (range) 12.7 (15.0) 17.2 (15.0–19.1) 21.1 (19.2–23.3) 26.1 (23.4–29.7) 35.3 (
29.7) —
Case/control subjects (n) 252/250 138/251 188/251 226/251 250/251 —
Model 1 1.0 0.54 (0.41–0.71) 0.75 (0.58–0.97) 0.89 (0.70–1.15) 0.99 (0.77–1.27) 0.11
Model 2 1.0 0.76 (0.55–1.04) 0.90 (0.67–1.21) 0.95 (0.71–1.28) 0.82 (0.62–1.10) 0.46
Model 2  HMW adiponectin 1.0 0.73 (0.52–1.02) 0.85 (0.62–1.17) 0.90 (0.66–1.23) 0.80 (0.59–1.08) 0.39
sOB-R (ng/ml), median (range) 20.4 (22.9) 25.0 (22.9–27.0) 28.9 (27.1–30.8) 33.9 (30.9–36.9) 42.0 (
36.9) —
Case/control subjects (n) 268/250 260/251 205/251 192/251 129/251 —
Model 1 1.0 0.96 (0.75–1.22) 0.76 (0.59–0.97) 0.71 (0.55–0.92) 0.47 (0.36–0.62) 0.0001
Model 2 1.0 0.73 (0.55–0.96) 0.51 (0.38–0.68) 0.42 (0.31–0.57) 0.39 (0.28–0.54) 0.0001
Model 2  HMW adiponectin 1.0 0.83 (0.62–1.12) 0.62 (0.46–0.84) 0.61 (0.44–0.84) 0.67 (0.47–0.95) 0.005
Multivariate model 1 was adjusted for matching factors only (age at blood draw, date of blood draw, fasting status [8 h vs. 8 h since last
meal], and race). Model 2 was further adjusted for BMI (kg/m
2), smoking status (never smoked, past smoker, or current smoker),
postmenopausal status (yes, no), hormone use (never used, past user, current user), family history of diabetes (yes, no), physical activity (in
quintiles), intake of alcohol, cereal ﬁber, heme iron, trans fat, and magnesium, and coffee and red meat consumption (all in quintiles).
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deﬁcient animal models and humans supported a beneﬁ-
cial effect of leptin on insulin sensitivity or type 2 diabetes
(43–47), prospective epidemiologic data on circulating
leptin levels and future risk of type 2 diabetes have been
mixed in subjects with normal leptin secretion ability
(6–14). In humans, leptin levels are strongly correlated
with subcutaneous adiposity, reﬂecting leptin resistance in
obese individuals. To remove the confounding effects of
BMI, we examined BMI-adjusted leptin levels in relation to
diabetes risk. In our study, BMI-adjusted leptin levels were
not signiﬁcantly associated with diabetes risk. However,
our data suggest that the association between leptin and
type 2 diabetes was modulated by BMI. Leptin levels
tended to be associated with a lower risk among relatively
obese subjects. Two previous studies also found a similar
association (8,14). One possible explanation for the posi-
tive association between leptin and diabetes risk in lean
participants could be that high leptin levels reﬂected the
amount of adipose tissue that was not captured by BMI,
although further adjustment for waist circumference did
not change our observation. The beneﬁcial effects of high
leptin levels on diabetes risk in overweight or obese
people may be related to the peripheral effects of leptin on
insulin sensitivity rather than its effects on weight regula-
tion (5) because in the cerebrospinal ﬂuid free leptin levels
are already saturated at low levels of circulating leptin
levels (48). Whether high leptin levels in lean people
represent a deteriorating metabolic status needs further
examination.
The current study has several strengths. The prospec-
tive study design made it unlikely that disease status or
treatment may inﬂuence the leptin or sOB-R levels (i.e.,
that reverse causation occurred). In addition, we used
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
15 20 25 30 35 40 45 50
Plasma sOB-R levels (ng/mL)
O
d
d
s
 
r
a
t
i
o
 
(
9
5
%
 
C
I
)
 
o
f
 
t
y
p
e
 
2
 
d
i
a
b
e
t
e
s
A
0.4
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
1.3
1.4
5 1 01 52 02 53 03 54 04 5
Plasma leptin levels (ng/mL)
O
d
d
s
 
r
a
t
i
o
 
(
9
5
%
 
C
I
)
 
o
f
 
t
y
p
e
 
2
 
d
i
a
b
e
t
e
s
B
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levels were excluded to minimize potential impact of outliers. Multi-
variate logistic regression models were adjusted for the same set of
covariates for model 2 in Table 3. BMI as a continuous variable was
further adjusted for in these models. Solid lines are ORs and dashed
lines are 95% CIs. A: sOB-R. B: Leptin.
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for the same set of covariates for model 2 in Table 3. BMI as a
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Q. SUN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 615BMI-adjusted residuals of leptin biomarkers in the current
analysis to more completely control for strong confound-
ing by BMI. Other strengths include a large sample size,
long follow-up period, validated approach for conﬁrming
type 2 diabetes case subjects, and adjustment for a multi-
tude of risk factors for type 2 diabetes.
Several limitations merit discussion as well. First, in
observational studies, residual confounding, especially the
confounding by adiposity not captured by BMI and waist
circumference in the current study, cannot be entirely
ruled out. In addition, some covariates were assessed at
different time points, which may lead to potentially incom-
plete controlling for confounding by these factors. Second,
a single baseline measurement of leptin or sOB-R levels
may not represent the long-term levels of these markers.
However, leptin levels have been shown to be quite stable
over time (49). Similar to adiponectin, the short-term
variation of sOB-R levels was relatively small (50). Third,
because our study sample included only middle-aged
women who were predominantly white, it is unclear
whether the results can be generalized to men and other
ethnic groups.
In conclusion, we found a strong, inverse association
between circulating soluble leptin receptor levels and risk
of type 2 diabetes, independent of obesity and leptin
levels. On the other hand, the association between leptin
and diabetes risk may be modiﬁed by adiposity. Biological
mechanisms underlying these novel observations need to
be further elucidated.
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